Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007925 | 0.81 | L3MBTL1 (0.61) | RAB9ASMN1; SMN2MAPK10L3MBTL1MAPK1 | |
| SCHEMBL14774791 | 0.81 | TSHR (0.65) | RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL14774966 | 0.80 | HPGD (0.51) | RAB9ASMN1; SMN2L3MBTL1NPC1MAPT | |
| SCHEMBL30008144 | 0.80 | RAB9A (1.00) | RAB9ASMN1; SMN2L3MBTL1MAPK1NPC1 | |
| SCHEMBL1848793 | 0.78 | L3MBTL1 (0.61) | RAB9ASMN1; SMN2MAPK10L3MBTL1MAPK1 | |
| SCHEMBL31241121 | 0.78 | RAB9A (0.62) | RAB9ASMN1; SMN2MAPK10L3MBTL1MAPK1 | |
| SCHEMBL31241142 | 0.77 | SMN1; SMN2 (0.71) | RAB9ASMN1; SMN2MAPK10L3MBTL1MAPT | |
| SCHEMBL31241128 | 0.77 | RAB9A (0.60) | RAB9ASMN1; SMN2MAPK10L3MBTL1MAPK1 | |
| SCHEMBL31241071 | 0.76 | RAB9A (0.97) | RAB9ASMN1; SMN2L3MBTL1MAPK1NPC1 | |
| SCHEMBL1849856 | 0.75 | SMN1; SMN2 (0.73) | RAB9ASMN1; SMN2L3MBTL1MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812505-A | PI5P4K gamma inhibitor compound, pharmaceutical composition, and preparation method and application thereof | 贵州医科大学 | 2024-10-22 | — | — | CN | disclosed |
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | RAB9A 2566/4885SMN1; SMN2 1852/4885MAPK10 2423/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | RAB9A 2566/4885SMN1; SMN2 1852/4885MAPK10 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.